Scientific Publications by FDA Staff

J Virol Methods 2011 Jun;174(1-2):99-109

Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins.

Ou W, Delisle J, Konduru K, Bradfute S, Radoshitzky SR, Retterer C, Kota K, Bavari S, Kuhn JH, Jahrling PB, Kaplan G, Wilson CA

Ebolaviruses are the etiologic agents of severe viral hemorrhagic fevers in primates, including humans, and could be misused for the development of biological weapons. The ability to rapidly detect and differentiate these viruses is therefore crucial. Antibodies that can detect reliably the ebolavirus surface envelope glycoprotein GP(1,2) or a truncated variant that is secreted from infected cells (sGP) are required for advanced development of diagnostic assays such as sandwich ELISAs or Western blots (WB). We used a GP(1,2) peptide conserved among Bundibugyo, Ebola, Reston, Sudan, and Taï Forest viruses and a mucin-like domain-deleted Sudan virus GP(1,2) (SudanGP¿Muc) to immunize mice or rabbits, and developed a panel of antibodies that either cross-react or are virus-specific. These antibodies detected full-length GP(1,2) and sGP in different assays such as ELISA, FACS, or WB. In addition, some of the antibodies were shown to have potential clinical relevance, as they detected ebolavirus-infected cells by immunofluorescence assay and gave a specific increase in signal by sandwich ELISA against sera from mouse-adapted Ebola virus-infected mice over uninfected mouse sera. Rabbit anti-SudanGP¿Muc polyclonal antibody neutralized gammaretroviral particles pseudotyped with Sudan virus GP(1,2), but not particles pseudotyped with other ebolavirus GP(1,2). Together, our results suggest that this panel of antibodies may prove useful for both in vitro analyzes of ebolavirus GP(1,2), as well as analysis of clinically relevant samples.